Morepen Laboratories Ltd

- The company is open to raising capital but has not started any formal process yet (Page 13). - Informal discussions are ongoing with associates and advisors regarding fundraising (Page 13). - There is openness to bringing in equity players either in the medical devices subsidiary or in the parent company (Page 22). - No specific timelines or amounts have been provided; plans will be announced once finalized (Page 13, 22). - The company is also open to partnerships, M&A, and inviting new investors to the board to support growth (Page 22). - Previously, inability to access the market limited fundraising, but the current situation is described as a "historical moment" allowing for capital infusion (Page 22). - No mention of new debt raising; focus appears to be more on equity capital raising.

- Capex of around ₹22 Crores planned for the year, including ₹12 Crores spent and ₹5 Crores work in progress (Page 20). - ₹45 Crores investment in medical devices over nine months, showing significant focus on this segment (Page 20). - Expansion planned to increase capacity from 300 KL to 1000 KL over three years for API segment, requiring additional capex (Page 19). - Setting up plant for ANDA and ABS, but filing is 2 years away due to validation process (Page 21). - Demerger of medical devices business into a separate 100% owned subsidiary to attract better capital, customers, and talent (Page 14). - Increased R&D spending (up 58%) primarily in API and finished dosages, with plans to ramp up further as topline grows (Page 12). - Heavy investments in meters and marketing for medical devices, including celebrity endorsements, to expand market reach (Pages 7, 11). - Open to bringing equity investors or partners via M&A to support growth, including in medical devices or parent company (Page 22).

- The company has maintained a historical CAGR revenue growth of around 25%, currently achieving 30% growth, and is comfortable sustaining 20-30% CAGR going forward. - Medical devices segment has grown at a CAGR of approximately 41-46% and is expected to continue strong growth with capacity expansions and wider market reach. - Online sales have surged significantly, with a 441% increase quarter-on-quarter and 30-40% ongoing quarterly growth, indicating strong future momentum. - Expansion in API production capacity planned from 300 KL to 1000 KL over 3 years to meet growing demand, enabling exponential sales growth through new molecule opportunities. - New product launches (e.g., US FDA-approved Fexofenadine, Dapagliflozin, fertility range) and increased marketing investments are expected to further drive topline growth. - The forthcoming authorization for Sputnik vaccine production could open a substantial new revenue stream, though dependent on bulk supply availability. - Strategic focus on global markets, particularly in neighboring countries and beyond, to capture larger market share.

- The company targets a compounded annual growth rate (CAGR) of 25% to 30% in sales across businesses. - Medical devices have exhibited higher growth rates (~41% CAGR) but such high growth may normalize due to small base effects. - Continued investments in medical devices and online channels are expected to boost future topline and profitability. - EBITDA margins may see short-term compression due to heavy investments in marketing and devices, but long-term margins are expected to improve as scale increases. - OTC business currently margin-light due to investments but expected to improve with market traction. - R&D spend is increasing aiming to capture opportunities from 15 APIs going off-patent through 2030, targeting 10% global market share in key APIs. - Overall earnings/profits expected to improve as new capacities come online and investments mature. - Management confident of exponential sales growth with better capital access and expanded capacities.

- Morepen Laboratories is expecting approval for the Sputnik vaccine drug license. - Once approved, they plan to sign an agreement with RDIF, with bulk supply expected from Serum. - Production capacity for Sputnik vaccine is up to 5 million units per month (about 25 million dosages). - Actual production quantity depends on bulk supply from RDIF or Serum; no fixed estimate currently. - Demand is driven by Russia's high COVID case counts (150,000 daily) and need in third-world countries. - WHO approval of Sputnik is anticipated to trigger orders. - The situation is dynamic ("moving parts"), so Morepen is cautiously optimistic but unable to provide firm orderbook numbers at present.